Adrenocortical cancer (ACC) is a rare cancer with poor prognosis and scant treatment options. Mitotane alone, or in combination with cytotoxic chemotherapy, represents the referral current treatment for patients with unresectable ACC. Recent studies have shown that mTOR inhibitors suppress growth of ACC cells. AIM This study aimed at evaluating the effects of mitotane in combination with sirolimus, an mTOR inhibitor, in ACC cell lines.
COMBINED EFFECTS OF SIROLIMUS AND MITOTANE IN THE INHIBITION OF GROWTH OF HUMAN ADRENOCORTICAL CARCINOMA CELLS CONCLUSIONS
The current study demonstrates that sirolimus has additive antiproliferative effects when combined with low mitotane doses. These doses correspond to concentrations lower than the therapeutic range of mitotane. If this effect can also be achieved in vivo, our data suggest that the addition of sirolimus to mitotane might be useful in ACC patients when the therapeutic range of mitotane range is not reached. RESULTS  In H295, mitotane significantly inhibited cell proliferation at all concentrations tested, with an IC50 of 4.5*10 -6 M and a maximal inhibition of 87% as compared with vehicle-treated controls (p<0.001). In SW13, mitotane significantly inhibited cell proliferation at concentrations higher than 2.5x10 -6 M, with an IC50 of 1.6x10 -5 M and a maximal inhibition of 81% as compared with vehicle-treated controls (p<0.001) (figure 1). In both H295 and SW13 sirolimus significantly inhibited cell proliferation at both concentrations tested and when combined with mitotane, it showed statistically significant additive effects. This additivity was observed only with low mitotane doses (between 10 -7 -5*10 -6 M) (figure 1). Using mitotane doses higher than 5*10 -6 M the cell proliferation inhibition was already nearly maximal and no significant additive effects could be observed (figure 1). The addition of sirolimus to mitotane did not significantly change the dose response curve of mitotane (figure 2). 
